Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
IMRX Immuneering
3.910
+0.030+0.77%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Assets
Current assets
Cash, cash equivalents and short term investments
-21.60% 117.2M 154.95% 128.1M 345.37% 137.77M 302.26% 149.2M
-Cash and cash equivalents
-28.53% 76.42M 75.02% 87.94M 143.12% 75.21M 101.91% 74.89M
-Short-term investments
-4.16% 40.78M -- 40.16M -- 62.57M -- 74.31M
Receivables
-85.11% 70.18K -63.96% 178.43K -43.21% 279.61K -50.80% 246.04K
-Accounts receivable
-85.11% 70.18K -63.96% 178.43K -43.21% 279.61K -50.80% 246.04K
Prepaid assets
-17.98% 2.76M 27.81% 890.41K 95.56% 1.48M 1,949.27% 2.89M
Total current assets
-21.71% 120.02M 151.12% 129.17M 333.56% 139.53M 303.73% 152.33M
Non current assets
Net PPE
841.27% 5.82M 780.23% 5.68M 764.40% 5.71M 805.05% 6.13M
-Gross PPE
692.71% 6.17M 651.34% 5.95M 643.10% 5.93M 682.13% 6.31M
-Accumulated depreciation
-116.15% -344.56K -87.54% -276.48K -61.26% -221.92K -35.31% -174.22K
Goodwill and other intangible assets
-- 7.11M -- 7.11M -- 7.12M -- 7.14M
-Goodwill
-- 6.69M -- 6.69M -- 6.69M -- 6.7M
-Other intangible assets
-- 416.26K -- 423.58K -- 430.9K -- 439K
Investments and advances
-- 0 -- 0 -- 0 -- 996.56K
Other non current assets
5,044.02% 737.29K -90.67% 89.58K 524.98% 89.58K 612.54% 102.13K
Total non current assets
27.35% 13.67M 702.36% 12.88M 1,815.15% 12.92M 1,977.31% 14.37M
Total assets
-18.50% 133.69M 167.81% 142.05M 363.97% 152.45M 333.87% 166.7M
Liabilities
Current liabilities
Payables
30.26% 2.34M -13.42% 1.24M 19.99% 1.64M -5.82% 1.39M
-accounts payable
30.26% 2.34M -13.42% 1.24M 19.99% 1.64M -5.82% 1.39M
Current accrued expenses
34.68% 4.56M -32.91% 2.23M 31.12% 1.72M 467.31% 3.97M
Current debt and capital lease obligation
272.84% 308.69K 255.28% 286.37K 238.34% 265.42K 259.06% 274.04K
-Current capital lease obligation
272.84% 308.69K 255.28% 286.37K 238.34% 265.42K 259.06% 274.04K
Other current liabilities
-- 44.56K -- 47.21K -- 47.21K -- --
Current liabilities
37.76% 7.26M -21.35% 3.8M 33.20% 3.67M 149.74% 5.63M
Non current liabilities
Long term debt and capital lease obligation
842.53% 4.54M 823.01% 4.64M 798.13% 4.71M 834.51% 5.09M
-Long term capital lease obligation
842.53% 4.54M 823.01% 4.64M 798.13% 4.71M 834.51% 5.09M
Preferred securities outside stock equity
-- -- -- -- -- -- -- 0
Other non current liabilities
-- -- -- 9.9K -- 9.9K -- --
Total non current liabilities
842.53% 4.54M -94.42% 4.65M 800.02% 4.72M -91.32% 5.09M
Total liabilities
105.23% 11.8M -90.42% 8.46M 155.65% 8.39M -82.39% 10.72M
Shareholders'equity
Share capital
1.80% 26.41K 400.23% 26.39K 95.27% 26.38K 431.72% 26.32K
-common stock
1.80% 26.41K 400.23% 26.39K 95.27% 26.38K 431.72% 26.32K
-Preferred stock
-- 0 -- 0 -- 0 -- --
Retained earnings
-99.10% -96.54M -109.48% -83.7M -125.76% -72.17M -130.30% -59.27M
Paid-in capital
5.70% 218.55M 4,464.48% 217.45M 251.65% 216.37M 6,521.36% 215.28M
Gains losses not affecting retained earnings
-2,898.80% -142.47K -- -181.56K -- -167.4K -- -49.01K
Total stockholders'equity
-23.00% 121.89M 479.68% 133.59M 387.09% 144.06M 793.82% 155.98M
Total equity
-23.00% 121.89M 479.68% 133.59M 387.09% 144.06M 793.82% 155.98M
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Immuneering Corp. engages in the development of new medicines which are unlikely to be found by traditional drug discovery methods. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.
CEO: Dr. Benjamin J. Zeskind, PhD
Market: NASDAQ
Listing Date: 07/30/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist